Compare · A vs ASTC
A vs ASTC
Side-by-side comparison of Agilent Technologies Inc. (A) and Astrotech Corporation (DE) (ASTC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both A and ASTC operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- A is the larger of the two at $36.25B, about 1252.8x ASTC ($28.9M).
- Over the past year, A is up 10.6% and ASTC is up 163.6% - ASTC leads by 153.0 points.
- A has been more active in the news (15 items in the past 4 weeks vs 6 for ASTC).
- A has more recent analyst coverage (25 ratings vs 0 for ASTC).
- Company
- Agilent Technologies Inc.
- Astrotech Corporation (DE)
- Price
- $128.36-1.68%
- $15.71-6.77%
- Market cap
- $36.25B
- $28.9M
- 1M return
- +14.90%
- +516.08%
- 1Y return
- +10.56%
- +163.59%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1999
- News (4w)
- 15
- 6
- Recent ratings
- 25
- 0
Agilent Technologies Inc.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software, information management, and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment to produce synthesized oligonucleotide. It also offers immunohistochemistry, in situ hybridization, and hematoxylin and eosin staining and special staining; instruments, consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. It has collaboration agreement with SGS AXYS. The company was incorporated in 1999 and is headquartered in Santa Clara, California.
Astrotech Corporation (DE)
Astrotech Corporation operates as a science and technology development and commercialization company worldwide. It operates through three segments, Astrotech Technologies, Inc. (ATI), 1st Detect Corporation (1st Detect), and AgLAB Inc (AgLAB). The ATI segment owns and licenses the AMS Technology, the platform mass spectrometry technology. The 1st Detect segment manufactures explosives and narcotics trace detectors for use at airports, secured facilities, and borders. This segment provides TRACER 1000, a mass spectrometer based explosives trace detector to replace the explosives trace detectors used at airports, cargo and secured facilities, and borders. The AgLAB segment develops AgLAB-1000, a mass spectrometer for use in the hemp and cannabis market. It also develops BreathTest-1000, a breath analysis tool to screen for volatile organic compound metabolites found in a person's breath. The company was formerly known as SPACEHAB, Inc. and changed its name to Astrotech Corporation in 2009. Astrotech Corporation was incorporated in 1984 is based in Austin, Texas.
Latest A
- Piper Sandler initiated coverage on Agilent with a new price target
- New insider Downs Timothy Charles claimed ownership of 8,872 shares (SEC Form 3)
- President and CEO Mcdonnell Padraig covered exercise/tax liability with 418 shares, decreasing direct ownership by 0.63% to 65,842 units (SEC Form 4)
- Agilent, OpenAI, BCG Collaborate to Accelerate Customer-Focused, AI-Driven Scientific Innovation
- Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma
- Director Dolsten Mikael sold $216,672 worth of shares (1,600 units at $135.42), decreasing direct ownership by 22% to 5,548 units (SEC Form 4)
- SEC Form 10-Q filed by Agilent Technologies Inc.
- SEC Form SD filed by Agilent Technologies Inc.
- Agilent upgraded by BofA Securities with a new price target
- Agilent Introduces OpenLab Sync to Support Guided, Digital Execution in the Laboratory
Latest ASTC
- Astrotech Corporation (DE) filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Astrotech Board Approves Potential Sale Process of 1st Detect and TRACER 1000, the Only Field-Deployed Mass Spectrometry ETD, as the Company Focuses on Its Initiative in Space
- Astrotech Corporation's 1st Detect TRACER 1000 Receives ECAC Certification for Wand Swabbing
- Astrotech Corporation (DE) filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form 424B5 filed by Astrotech Corporation (DE)
- Astrotech Corporation Board of Directors Approves Strategic Lunar Resource and Infrastructure Initiative to Advance Future Moon-Based Quantum Computing Manufacturing
- Director Wilkinson Tom was granted 6,006 shares, increasing direct ownership by 25% to 29,868 units (SEC Form 4)
- EN-SCAN Launches Labrador HH-GC, Engineered to Deliver Laboratory-Grade VOC Analysis Directly in the Field
- Director Winn Charles Arch was granted 6,006 shares, increasing direct ownership by 154% to 9,895 units (SEC Form 4)
- Director Halinski John William was granted 6,006 shares, increasing direct ownership by 200% to 9,006 units (SEC Form 4)